Table 3 Peak and AUC0-28 anti-CD19 CAR T-cell levels by remission status in pooled Phase 1 and 2 patients.

From: Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

 

Ongoing remission at analysis data cutoffa

Ongoing CR/CRi (n = 9)

Relapsed (n = 23)

Non-CR/CRi (n = 21)

AUC0-28 (cells/μL×days)

   

 n

7

19

18

 Median (range)

698.1 (185.8–1122.6)

263.1 (15.3–2624.5)

32.1 (0–642.3)

Peak (cells/μL)

   

 n

7

19

18

 Median (range)

63.0 (21.9–84.0)

23.3 (2.2–322.2)

2.5 (0–183.5)

  1. AUC0-28 area under the curve between days 0 and 28, CAR chimeric antigen receptor, CR complete remission, CRi complete remission with incomplete hematologic recovery.
  2. aOngoing CR/CRi is defined as patients with CR or CRi at analysis data cutoff. Relapsed is defined as patients with a best response of CR or CRi who subsequently relapsed or died by analysis data cutoff. Non-CR/CRi is defined as subjects who had neither CR nor CRi by analysis data cutoff. Patients who had the following events by analysis data cutoff are not included in the ongoing outcome assessment: allogeneic stem cell transplantation, started new anticancer therapy, withdrawal of consent, or lost to follow-up.
Back to article page